STOCK TITAN
  1. Home
  2. News
  3. SKYE

Skye Bioscience Inc - SKYE STOCK NEWS

Welcome to our dedicated news page for Skye Bioscience (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Skye Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Skye Bioscience's position in the market.

News
Skye Bioscience to Present at Upcoming Investment Conferences
Rhea-AI Summary
Skye Bioscience, a clinical-stage biotechnology company, will present at upcoming investment conferences to showcase its programs in obesity and glaucoma. CEO Punit Dhillon and team members will discuss the company's focus on developing therapeutic drugs that target the endocannabinoid system. The conferences include BTIG Obesity Day on May 8, 2024, Citizens JMP Life Sciences Conference on May 13-14, and Jefferies Global Healthcare Conference on June 5-6, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.27%
Tags
conferences
-
News
Skye Bioscience Uplists to The Nasdaq Global Market
Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) has received approval to list its common stock on the Nasdaq Global Market, moving from the OTCQB. The company's stock will trade under the ticker symbol 'SKYE', aiming to enhance visibility, attract more investors, and increase long-term shareholder value. Skye's CEO anticipates positive clinical data and the launch of a new clinical trial in the upcoming quarters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.69%
Tags
none
-
News
Skye Bioscience Announces $40 Million Private Placement Equity Financing
Rhea-AI Summary
Skye Bioscience, Inc. secures $40 million in financing through a private placement to fund obesity clinical development and extend operational capabilities beyond 2026. The company plans to utilize the funds to advance the development of nimacimab, a unique peripheral CB1 inhibitor for obesity treatment. Notable investors in the financing include Perceptive Advisors, Velan Capital, and Schonfeld Strategic Advisors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.95%
Tags
none
News
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
Rhea-AI Summary
Skye Bioscience, Inc. appoints Dr. Annalisa Jenkins, a seasoned pharmaceutical industry leader, to its Board of Directors. Dr. Jenkins brings over 25 years of experience in global pharmaceuticals, biotechnology, and life sciences, with a focus on developing new products across various disease areas. Her expertise in leading teams and developing strategies will aid Skye in advancing its therapeutic drugs for obesity and ocular indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags
management
-
News
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
Rhea-AI Summary
Skye Bioscience, Inc. completes targeted patient enrollment ahead of schedule for its Phase 2a study of SBI-100 Ophthalmic Emulsion, a CB1 agonist for elevated intraocular pressure in glaucoma and ocular hypertension patients. Positive Phase 1 trial results indicate safety, tolerability, and efficacy potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.82%
Tags
clinical trial
-
News
Skye Bioscience to Present at Oppenheimer Investor Conference
Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) to present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference on February 13-14, 2024, showcasing its programs in obesity and glaucoma. CEO Punit Dhillon and executive team to hold 1x1 meetings. The presentation will be webcast and available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.55%
Tags
conferences
News
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
Rhea-AI Summary
Skye Bioscience, Inc. has announced a securities purchase agreement for the sale of common stock and pre-funded warrants, with gross proceeds of $50.25 million from a PIPE financing co-led by a life sciences-focused investor and 5AM Ventures. The financing is expected to fund operations into early 2026, including Phase 2 clinical trials for nimacimab in obesity and SBI-100 OE in glaucoma and ocular hypertension. The company is also planning a Phase 2 trial randomizing obese patients to test the efficacy of nimacimab and GLP-1R agonist in weight loss. Skye's CEO, Punit Dhillon, expressed optimism about the potential impact of CB1-modulating therapies in treating obesity and glaucoma, emphasizing the scientific validation of nimacimab's mechanism of action and the need for alternative intraocular pressure-lowering drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.03%
Tags
none
-
News
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) receives FDA clearance to initiate Phase 2 clinical trial of nimacimab, a peripherally-acting CB1 inhibitor, targeting obesity and chronic kidney disease. Nimacimab shows promising safety and tolerability in Phase 1b study, with encouraging trends in exploratory biomarkers. The molecule offers potential as a single or combination therapy for metabolic conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.44%
Tags
clinical trial
-
News
Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab
Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) plans to develop nimacimab, a monoclonal antibody targeting the endocannabinoid system, for weight loss and obesity treatment. The Company filed an IND application with the FDA for a Phase 2 study in patients with obesity and chronic kidney disease. Nimacimab's safety profile is encouraging, showing potential for monthly dosing and convenient patient self-administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
clinical trial
News
Skye Bioscience Responds to OTC Markets Promotional Policy
Rhea-AI Summary
Skye Bioscience, Inc. (OTCQB: SKYE) Receives Request from OTC Markets Group Inc. for Statement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock SKYE logo
Skye Bioscience Inc

Nasdaq:SKYE

SKYE Rankings

#3246 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SKYE Stock Data

362.29M
11.67M
7.09%
57.67%
General Freight Trucking, Long-Distance, Truckload
Transportation and Warehousing
Link
US
San Diego

About SKYE

nemus bioscience is a publicly traded, life-science biotech company, developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need.